BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7678546)

  • 1. Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins.
    Matin A; Hung MC
    Cancer Lett; 1993 Jan; 68(1):55-60. PubMed ID: 7678546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
    Reardon DB; Hung MC
    J Biol Chem; 1993 Aug; 268(24):18136-42. PubMed ID: 7688739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
    Bargmann CI; Weinberg RA
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF; Heffernan PA; Weinberg RA
    Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
    Cao H; Decker S; Stern DF
    Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF; Kamps MP; Cao H
    Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
    Yarden Y; Weinberg RA
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3179-83. PubMed ID: 2470093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
    Yu D; Shi D; Scanlon M; Hung MC
    Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
    Drebin JA; Link VC; Stern DF; Weinberg RA; Greene MI
    Cell; 1985 Jul; 41(3):697-706. PubMed ID: 2860972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
    Kamps MP; Sefton BM
    Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
    Connelly PA; Stern DF
    Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
    Muthuswamy SK; Muller WJ
    Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Zhang L; Chang CJ; Bacus SS; Hung MC
    Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene.
    Boccaccio C; Gaudino G; Cilli M; Mondino A; Comoglio PM
    Growth Factors; 1991; 5(3):233-42. PubMed ID: 1685656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function.
    Brandt-Rauf PW; Rackovsky S; Pincus MR
    Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8660-4. PubMed ID: 1978329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1.
    Cheatham B; Shoelson SE; Yamada K; Goncalves E; Kahn CR
    Proc Natl Acad Sci U S A; 1993 Aug; 90(15):7336-40. PubMed ID: 7688476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a neu/c-erbB-2 protein-specific activating factor.
    Dobashi K; Davis JG; Mikami Y; Freeman JK; Hamuro J; Greene MI
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8582-6. PubMed ID: 1717981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.